GlassScriptPhysician profile
Jonathan Eric Marston
NPI 1841376720
$3,356.90
in general payments reported to CMS, 2019-2025
38 companies · $825 in 2025
The $825 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $188 · 2021: $26.59 · 2022: $109 · 2023: $612 · 2024: $915 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.86 | 2023-2025 | |
| Lilly USA, LLC | $338.27 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Novo Nordisk INC | $257.52 | 2019-2025 | Wegovy |
| Pfizer INC. | $246.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $219.49 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $211.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.84 | 2019-2024 | Xifaxan |
| Abbott Laboratories | $169.07 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.97 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $145.86 | 2019 | |
| Lundbeck LLC | $138.72 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $116.51 | 2019-2024 | Breztri, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $96.31 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $81.84 | 2019-2023 | Vaxneuvance, Pneumovax 23, M-M-R II |
| Dexcom, INC. | $55.40 | 2024-2025 | Dexcom G6 Transmitter |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Marston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.